Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723073 · ClinicalTrials.gov registry record
Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 323
- Enrollment target
NCT00723073: Completed study, sponsored by Brigham and Women's Hospital.
NCT00723073 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 323 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00723073 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 323 participants
- Enrollment target
Study Summary
Invasive fungal infections are an important cause of morbidity and mortality in patients with neutropenia who are receiving chemotherapy for cancer. Early diagnosis of these infections is difficult and fever may be the only sign. A delay in treatment while a diagnosis is pursued may lead to increased morbidity and mortality. There are now several echinocandins available with similar in vitro spectrum of activity. Caspofungin is the only echinocandin Food and Drug Administration (FDA) approved for empiric antifungal therapy in febrile neutropenia. Although all echinocandin antifungal agents have similar spectrum of activity, there are limited data on the use of micafungin in patients with persistent fever and neutropenia (FN). In November 2006 the Pharmacy and Therapeutics Committee at Brigham \& Women's Hospital / Dana Farber Cancer Institute (BWH/DFCI) switched from caspofungin to micafungin as our formulary echinocandin. Given the limited clinical data on the use of micafungin as empiric antifungal therapy in patients with FN, we sought to evaluate the safety and effectiveness of micafungin, compared with caspofungin, for this indication using a sequential cohort analysis of patients treated before and after the formulary change at Brigham and Women's Hospital.
Primary Outcome
Overall favorable response was defined as achievement of successful treatment of baseline fungal infections, survival to hospital discharge, absence of breakthrough Ivasive fungal disese (IFD), and lack of advserse events (AE) attributable to treatment that led to discontinuation of echinocandin therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-05 |
What the finished NCT00723073 record still lists
NCT00723073 is an observational study that tracks outcomes without assigning an intervention. The registered 323 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00723073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00723073 about?
NCT00723073 is a clinical study titled "Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia". Invasive fungal infections are an important cause of morbidity and mortality in patients with neutropenia who are receiving chemotherapy for cancer. Early diagnosis of these infections is difficult and fever may be the only sign. A delay in treatment while a diagnosis is pursued may lead to increase...
What is the current status of trial NCT00723073?
This trial is currently completed. The enrollment target is 323 participants. The study started on 2008-01. Estimated completion is 2008-05.
Who is sponsoring clinical trial NCT00723073?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia